Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Outline
3. COPD definition - GOLD 2010
4. Changes in COPD definition
5. Lung function categories
6. FEV1/FVC ratio decreases with increasing age
7. Lung function in 1000 "COPD" patients
8. COPD severity - U.S.
9. COPD severity - England
10. COPD severity - BOLD
11. COPD progression (1)
12. COPD progression (2)
13. Natural history of chronic airflow obstruction
14. What is progression of COPD?
15. Diagnosed lung disease & function impairment
16. Disease prevalence
17. Prevalence of COPD
18. Prevalence of COPD 2006 update (1)
19. Prevalence of COPD 2006 update (2)
20. The PLATINO and BOLD studies
21. BOLD sites
22. Prevalence of GOLD 2 COPD
23. COPD prevalence, by sex, in U.S., 1980-2000
24. Decreasing prevalence in Spain?
25. No increase in Finland
26. Risk of COPD among smokers
27. Risk of COPD by age (10 year increase)
28. GOLD 2 COPD risk factors: never smoking men
29. GOLD 2 COPD risk factors: never smoking women
30. Biomass fuel and COPD in China
31. Early life exposures (1)
32. Early life exposures (2)
33. Hospitalizations
34. A paradigm of exacerbations (1)
35. A paradigm of exacerbations (2)
36. COPD exacerbation rate
37. COPD hospitalization rate
38. End-of-life - disease C (1)
39. COPD hospitalizations - U.S. (1980-2000)
40. COPD hospitalizations - U.S. (1990-2005)
41. Long-term follow-up of U.S. cohorts (1)
42. Risk of death following COPD hospitalization
43. Long-term follow-up of US cohorts (2)
44. Risk of hospitalization
45. Mortality
46. End-of-life - disease C (2)
47. Survival by lung function impairment
48. What do COPD patients die from?
49. COPD - consequences and comorbidities
50. Risk of death within 5 years from baseline
51. Mortality following exacerbation
52. COPD deaths by sex, race; U.S., 1980 - 2000
53. COPD deaths by region; U.S., 1980 - 2000
54. Improving survival after COPD hospitalization
55. Improving COPD mortality in U.S.
56. Conclusions (1)
57. Conclusions (2)
58. COPD is a preventable and treatable disease

Topics Covered

• GOLD guidelines for COPD
• Lung function categories
• BOLD initiative
• Exacerbation rates for COPD patients
• Hospitalization rates for COPD patients
• Reasons for mortality in COPD patients
• Update interview: An expanded definition of COPD from COPDGene
• Update interview: Key lung function trajectories in the development of COPD
• Update interview: Overlap syndromes with COPD, including asthma, pulmonary fibrosis, obstructive sleep apnea
• Update interview: Combination therapies in the treatment of COPD
• Update interview: Improvement in COPD metrics (hospitalization and mortality)

Links

Series:

• Advances in Chronic Obstructive Pulmonary Disease (COPD)

Categories:

• Clinical Practice

Therapeutic Areas:

• Respiratory Diseases

Talk Citation

Publication History

• Published on July 31, 2012
• Updated on June 27, 2021

Financial Disclosures

• Dr. David Mannino, Consultant: GlaxoSmithKline, Merck, Novartis, Nycomed, Forest; Speaker’s Bureau: Merck, GlaxoSmithKline; Grant/Research Support (Principal Investigator): GlaxoSmithKline, Forest, Boerhinger-Ingelheim.

Update Available

The speaker addresses developments since the publication of the original talk. We recommend listening to the associated update as well as the lecture.

1. Embed full lecture Full lecture Duration: 30:21 min Embed full lecture
2. Embed Update interview Update interview Duration: 12:43 min Embed Update interview